Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to findings from a phase I/II trial reported at the 2018 ASCO Annual Meeting.
Ibrutinib dose reduction was required in 35% of patients and buparlisib dose reduction in 41%. From 75% to 80% of patients required dose interruption for both drugs; 44% of patients had ibrutinib dose interruptions lasting at least 7 days, and 69% of patients had such interruptions with buparlisib.
Batlevi CL, De Frank S, Stewart C, et al. Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J Clin Oncol. 2018;36 (suppl; abstr 7520).
... to read the full story